Labskin is a commercial 3D in vitro skin model based on the original Leeds Model specifically developed for studying interactions between the skin and its microbiome. Further development of the microbiology protocols for growth, preparation, inoculation, and recovery have enabled Labskin to be used for a wide variety of applications in skin microbiology. The method of construction of the model using a fibrin rather than collagen based dermal matrix also provides for a more robust physical structure, which may have benefits for using Labskin in a wide variety of testing applications.
Get full access to this article
View all access options for this article.
References
1.
HollandDB, BojarRA, JeremyAHT, InghamE, HollandKT. Microbial colonization of an in vitro model of a tissue engineered human skin equivalent—a novel approach. FEMS Microbiol Lett, 2008:279; 110–115.
2.
FlamandN, MarrotL, BelaidiJ-P, et al.Development of genotoxicity test procedures with Episkin, a reconstructed human skin model: towards new tools for in vitro risk assessment of dermally applied compounds?. Mutat Res, 2006:606; 39–51.
3.
SchreiberS, MahmoudA, VuiaA, RübbelkeMK, SchmidtE, SchallerM. Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicol in Vitro, 2005:19; 813–822.
4.
SpielmannH, HoffmannS, LiebschM, BothamP, FentemJH, EskesC. The ECVAM international validation study on in vitro tests for acute skin irritation: Report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Altern Lab Anim, 2007:35; 559–601.
5.
PonecM. Skin constructs for replacement of skin tissues for in vitro testing. Adv Drug Deliv Rev, 2002:54; S19–30.
6.
NetzlaffF, LehrC-M, WertzPW, SchaeferUF. The human epidermis models EpiSkin, SkinEthic and EpiDerm: An evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur J Pharm Biopharm, 2005:60; 167–178.
7.
TornierC, RosdyM, MaibachHI. In vitro skin irritation testing on reconstituted human epidermis: Reproducibility for 50 chemicals tested with two protocols. Toxicol in Vitro, 2006:20; 401–416.
8.
HuT, KaluzhnyY, MunGC, BarnettB, KaretskyV, WiltN. Intralaboratory and interlaboratory evaluation of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay. Mutat Res, 2009:673; 100–108.
9.
KandárováH, LiebschM, SpielmannH, GenschowE, SchmidtE, TraueD. Assessment of the human epidermis model SkinEthic RHE for in vitro skin corrosion testing of chemicals according to new OECD TG 431. Toxicol in Vitro, 2006:20; 547–559.
10.
BouwstraJA, NahmoedN, GroeninkHWW, PonecM. Human skin equivalents are an excellent tool to study the effect of moisturizers on the water distribution in the stratum corneum. Int J Cosmet Sci, 2012:34; 560–566.
11.
FalangaV, IsaacsC, PaquetteD, DowningG, KouttabN, ButmarcJ. Wounding of bioengineered skin: Cellular and molecular aspects after injury. J Invest Dermatol, 2002:119; 653–660.
12.
KatohM, HataK. Refinement of LabCyte EPI-MODEL24 skin Irritation test method for adaptation to the requirements of OECD test guideline 439. ALTEX, 2011:16; 111–122.
13.
BaraiND, BoyceST, HoathSB, VisscherMO, KastingGB. Improved barrier function observed in cultured skin substitutes developed under anchored conditions. Skin Res Technol, 2008:14; 418–424.
14.
ThakoersingVS, GoorisGS, MulderA, RietveldM, El GhalbzouriA, BouwstraJA. Unraveling barrier properties of three different in-house human skin equivalents. Tissue Eng Part C Methods, 2012:18; 1–11.
15.
MajmudarG, JacobG, LaboyY. An in vitro method for screening skin-whitening products. J Cosmet Sci, 1998:49; 361–367.
16.
FacyV, FlouretV, RegnierM, SchmidtR. Langerhans cells integrated into human reconstructed epidermis respond to known sensitizers and ultraviolet exposure. J Invest Dermatol, 2004:122; 552–553.;
17.
FacyV, FlouretV, RégnierM, SchmidtR. Reactivity of Langerhans cells in human reconstructed epidermis to known allergens and UV radiation. Toxicol in Vitro, 2005:19; 787–795.
18.
CogenAL, NizetV, GalloRL. Skin microbiota: A source of disease or defence?. Br J Dermatol, 2008:158; 442–455.
19.
GriceE, KongH, RenaudG, YoungA, ProgramNCS, BouffardG. A diversity profile of the human skin microbiota. Genome Res, 2008:18; 1043–1050.
20.
GriceEA, KongHH, ConlanS, DemingCB, DavisJ, YoungAC., Topographical and temporal diversity of the human skin microbiome. Science, 2009:324; 1190–1192.
21.
GriceEA, SegreJA. The skin microbiome. Nate Rev Microbiol, 2011:9; 244–253.
22.
BojarRA, HollandKT. Review: The human cutaneous microflora and factors controlling colonisation. World J Microbiol and Biotechnol, 2002:18; 889–903.
23.
DuckneyP, WongHK, SerranoJ, YaradouD, OddosT, StamatasGN. The role of the skin barrier in modulating the effects of common skin microbial species on the inflammation, differentiation and proliferation status of epidermal keratinocytes. BMC Res Notes, 2013:6; 474.
24.
GalloRL, NakatsujiT. Microbial symbiosis with the innate immune defense system of the skin. J Investig Dermatol, 2011:131; 1974–1980.
25.
KongHH, SegreJA. Skin microbiome: looking back to move forward. J Investig Dermatol, 2012:132; 933–939.
26.
RosenthalM, GoldbergD, AielloA, LarsonE, FoxmanB. Skin microbiota: Microbial community structure and its potential association with health and disease. Infect Genet Evol, 2011:11; 839–848.
27.
LerebourG, CupfermanS, Bellon-FontaineMN. Adhesion of Staphylococcus aureus and Staphylococcus epidermidis to the Episkin reconstructed epidermis model and to an inert 304 stainless steel substrate. J Appl Microbiol, 2004:97; 7–16.
28.
BhattacharyyaT, EdwardM, CorderyC, RichardsonMD. Colonization of living skin equivalents by Malassezia furfur. Med Mycol, 1998:36; 15–19.
29.
de BreijA, HaismaEM, RietveldM, et al.Three-dimensional human skin equivalent as a tool to study Acinetobacter baumannii colonization. Antimicrob Agents Chemother, 2012:56; 2459–2464.
30.
MüllerG, LangerJ, SiebertJ, KramerA. Residual antimicrobial effect of chlorhexidine digluconate and octenidine dihydrochloride on reconstructed human epidermis. Skin Pharmacol Physiol, 2014:27; 1–8.
31.
PopovL, KovalskiJ, GrandiG, BagnoliF, AmievaMR. Three-dimensional human skin models to understand Staphylococcus aureus skin colonization and infection. Front Immunol, 2014:5; 41.
32.
El GhalbzouriA, LammeEN, van BlitterswijkC, KoopmanJ, PonecM. The use of PEGT/PBT as a dermal scaffold for skin tissue engineering. Biomaterials, 2004:25; 2987–2996.
33.
LeemingJP, NotmanFH. Improved methods for isolation and enumeration of Malassezia furfur from skin. J Clin Microbiol, 1987:25; 2017–2019.
